tiprankstipranks
Trending News
More News >
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
US Market
Advertisement

Silexion Therapeutics (SLXN) AI Stock Analysis

Compare
205 Followers

Top Page

SLXN

Silexion Therapeutics

(NASDAQ:SLXN)

Select Model
Select Model
Select Model
Underperform 34 (OpenAI - 4o)
Rating:34Underperform
Price Target:
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
Positive Factors
Strategic Partnership
The partnership with Catalent enhances Silexion's capabilities in siRNA development, potentially accelerating SIL204's path to market and strengthening its competitive position in targeting KRAS-driven cancers.
Innovative Product Development
The expanded SIL204 development plan, focusing on dual-route administration, addresses unmet needs in treating KRAS-driven pancreatic cancer, potentially positioning Silexion as a leader in innovative cancer therapies.
Positive Preclinical Results
The positive preclinical results for SIL204 validate its potential efficacy, supporting further clinical development and enhancing Silexion's prospects for regulatory approval and market entry.
Negative Factors
Zero Revenue
The lack of revenue generation is a critical issue, indicating challenges in monetizing products and sustaining operations, which could hinder long-term growth and financial stability.
Negative Equity
Negative equity reflects financial instability, limiting Silexion's ability to raise capital and invest in growth, posing risks to its long-term viability and operational capabilities.
High Leverage
High leverage increases financial risk, potentially straining cash flows and limiting strategic flexibility, which could impact Silexion's ability to navigate market challenges and invest in future growth.

Silexion Therapeutics (SLXN) vs. SPDR S&P 500 ETF (SPY)

Silexion Therapeutics Business Overview & Revenue Model

Company DescriptionSilexion Therapeutics (SLXN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for rare and complex diseases. Operating within the biotechnology and pharmaceuticals sector, Silexion Therapeutics specializes in creating targeted treatments that address unmet medical needs, leveraging advanced genetic and molecular technologies to develop its core products.
How the Company Makes MoneySilexion Therapeutics generates revenue primarily through the sale of its proprietary pharmaceutical products, which are developed in-house and marketed globally. The company also engages in licensing agreements with other pharmaceutical firms, allowing them to commercialize Silexion's patented technologies in exchange for royalties and milestone payments. Additionally, strategic partnerships with research institutions and healthcare providers contribute to its earnings by facilitating collaborative development projects and expanding its market reach.

Silexion Therapeutics Financial Statement Overview

Summary
Silexion Therapeutics faces significant financial challenges, including zero revenue and negative equity, posing major risks. While there is an improvement in net income and operating cash flow, the lack of revenue generation and high leverage create concerns for future sustainability.
Income Statement
20
Very Negative
Silexion Therapeutics has consistently reported zero revenue over the past three years, which is concerning for a company in the biotechnology industry. The net income improved significantly in 2024, turning positive after previous losses, indicating potential improvements in cost management or business operations. However, the lack of revenue generation remains a critical issue.
Balance Sheet
10
Very Negative
The balance sheet shows significant challenges, with stockholders' equity being negative in recent years and total liabilities exceeding total assets. The company's debt-to-equity ratio cannot be calculated due to negative equity, and this financial structure indicates high leverage and potential solvency risks. The absence of cash and cash equivalents in 2024 further adds to liquidity concerns.
Cash Flow
25
Negative
The cash flow position has seen some improvement, with operating cash flow increasing significantly towards a less negative figure in 2024. However, free cash flow remains negative, indicating ongoing challenges in generating cash from operations even though there is a positive shift in financing cash flow. The negative free cash flow to net income ratio suggests that the company is not yet in a stable cash generation position.
BreakdownTTMDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue0.000.000.000.00
Gross Profit-29.00K-25.00K0.000.00
EBITDA-17.93M-16.43M-4.64M-3.80M
Net Income-17.84M16.51M-4.94M-3.21M
Balance Sheet
Total Assets5.80M2.86M5.26M9.33M
Cash, Cash Equivalents and Short-Term Investments3.47M1.19M4.59M8.26M
Total Debt3.70M4.49M171.00K271.00K
Total Liabilities5.68M6.85M17.31M16.41M
Stockholders Equity120.00K-3.99M-15.48M-10.66M
Cash Flow
Free Cash Flow-10.56M-8.42M-4.54M-3.38M
Operating Cash Flow-10.54M-8.40M-4.53M-3.33M
Investing Cash Flow-23.00K-22.00K573.00K-524.00K
Financing Cash Flow12.34M5.10M522.00K2.75M

Silexion Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3.87
Price Trends
50DMA
6.51
Negative
100DMA
9.82
Negative
200DMA
14.64
Negative
Market Momentum
MACD
-0.82
Negative
RSI
36.10
Neutral
STOCH
68.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLXN, the sentiment is Neutral. The current price of 3.87 is above the 20-day moving average (MA) of 3.85, below the 50-day MA of 6.51, and below the 200-day MA of 14.64, indicating a neutral trend. The MACD of -0.82 indicates Negative momentum. The RSI at 36.10 is Neutral, neither overbought nor oversold. The STOCH value of 68.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SLXN.

Silexion Therapeutics Risk Analysis

Silexion Therapeutics disclosed 51 risk factors in its most recent earnings report. Silexion Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Silexion Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$20.34M-233.67%80.54%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
$7.69M-100.00%64.00%
39
Underperform
$13.61M-402.19%59.81%
34
Underperform
$8.22M-1342.57%-1475.99%
27
Underperform
$9.84M-658.62%99.45%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SLXN
Silexion Therapeutics
3.87
-47.17
-92.42%
PTNT
Palatin Technologies
7.90
-35.64
-81.86%
SNGX
Soligenix
1.37
-2.67
-66.09%
RNAZ
TransCode Therapeutics
11.80
-433.84
-97.35%
OCEA
Ocean Biomedical
0.01
-0.90
-98.90%
APLM
Apollomics
18.43
4.23
29.79%

Silexion Therapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Silexion Therapeutics Partners with Catalent for SIL204 Development
Positive
Apr 23, 2025

On April 23, 2025, Silexion Therapeutics announced a strategic collaboration with Catalent to develop advanced siRNA formulations and conduct clinical manufacturing activities for SIL204, their next-generation siRNA candidate. This partnership aims to optimize SIL204’s delivery formulations for targeting KRAS-driven cancers, building on promising preclinical results and supporting Silexion’s strategy to advance SIL204 toward clinical trials, with potential regulatory submissions planned for 2025 and 2026.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics is currently facing significant financial challenges, with zero revenue and negative equity posing major risks. The technical analysis reflects bearish momentum, and the valuation metrics highlight the speculative nature of the stock. However, recent corporate events, particularly the progress in SIL204, provide some optimism. Overall, the stock’s score is low, reflecting the high risks and uncertain future prospects.

To see Spark’s full report on SLXN stock, click here.

Product-Related AnnouncementsBusiness Operations and Strategy
Silexion Therapeutics Expands SIL204 Development Plan
Positive
Mar 28, 2025

On March 28, 2025, Silexion Therapeutics announced an expanded development plan for its siRNA candidate, SIL204, following promising preclinical data. The plan includes a dual-route administration strategy to treat KRAS-driven pancreatic cancer, integrating systemic and intratumoral delivery methods. This approach aims to address the aggressive nature of KRAS-driven cancers, characterized by high mortality and limited treatment options. Building on previous clinical results, Silexion plans further studies and regulatory submissions in 2025 and 2026, potentially advancing SIL204 into the next stage of clinical development.

Product-Related AnnouncementsBusiness Operations and Strategy
Silexion Therapeutics Reports Positive Data for SIL204
Positive
Mar 5, 2025

On March 5, 2025, Silexion Therapeutics announced positive initial data from the systemic administration of SIL204 in orthotopic pancreatic cancer models. The data demonstrated SIL204’s efficacy in reducing both primary tumor growth and metastatic spread, marking a significant advancement in their development program. The findings validate SIL204’s effectiveness in a clinically relevant setting and suggest potential for treating both primary and metastatic pancreatic cancer with a minimally-invasive delivery method. Silexion is exploring an expanded development plan for SIL204 based on these results.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 24, 2025